CRDF

Cardiff Oncology, Inc.

1.74 USD
+0.06 (+3.57%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cardiff Oncology, Inc. stock is up 13.73% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45% of the previous 19 February’s closed higher than January.

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.